Navigation Links
BrachySource® I-125 Seed, Calibrated

ProductsBrachySource® I-125 Seed, Calibrated
Company C. R. Bard, Inc.
Item BrachySource® I-125 Seed, Calibrated
Features 
  • 100% Assay of Seeds helps assure a consistently correct activity level delivered to physicist.
  • Flat Ends Minimizes migration.
  • Thick Titanium seed wall gives less opportunity for crushing (especially in Mick applicator).
  • 3.8 mm Gold Marker gives a good Fluoro visibility.
  • Excellent CT visibility gives an accurate post-operative dosimetry.
Description The BrachySource iodine-125 implant is a combination of innovative design, consistently reliable dosimetry, and remarkable visibility that makes BrachySource I-125 implant an ideal choice for your brachytherapy patients. You can be confident that every BrachySource I-125 implant order is backed by our seed management services which is required by clinicians who must meet the time-critical demands of brachytherapy.
Info C. R. Bard, Inc.
Customer Service: (800) 367-2273
Web site: http://www.crbard.com

Related medicine products :

1. BrachySource® I-125 Seed, Preloaded in Needle
2. BrachySource® I-125 Seed, Loose
3. IsoSeed I-125 (I25.S06)
4. Prospera® I-125 Seeds
5. TheraSeed® Pd-103 Seed, Calibrated
6. TheraSeed® Pd-103 Seed, Loose
7. TheraSeed® Pd-103 Seed, Preloaded in Needle
8. 5.0mm Calibrated Trephine Handle
9. 5.5mm Calibrated Trephine Handle
10. 6.25mm Calibrated Trephine Handle
11. 6.0mm Calibrated Trephine Handle
Breaking Medicine Technology:Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 1Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 2Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 3Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 4Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 5Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 6Study Shows That Diets of Infants are Improving 3B Concerns Remain for Toddlers and Preschoolers 59710 7Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 14517 1Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 14517 2Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 14517 3New chromosomal abnormality identified in leukemia associated with Down syndrome 10408 1New chromosomal abnormality identified in leukemia associated with Down syndrome 10408 2New chromosomal abnormality identified in leukemia associated with Down syndrome 10408 3